Evicenter
MarkdownMedical informationP&T meetings
Palazestrant (OP-1250)

Previously treated ER-positive HER2-negative advanced or metastatic breast cancer

Manufacturer
Olema Oncology
Last updated
256 sources

Product information and disease descriptionProduct descriptionProduct informationDrug/Drug, drug/disease interactions

Effects of Palazestrant on other drugs

8 evidence topics · 6 sources

Steady-state ribociclib parameters with and without palazestrant
Steady-state parameterRibociclib single agentRibociclib in combination with palazestrant
AUC0-24 ([h*ng/mL]/mg), GeoMean (GeoCV); N“23,800 (66%); 54”“25,400 (78%); 8”
Cmax (ng/mL/mg), GeoMean (GeoCV); N“1,820 (62%); 57”“1,860 (66%); 8”
Tmax (h), median (min–max); N“2.4 (0.68–7.8); 57”“4.0 (1.0–6.0); 8”